The effect of dalargin on growth factors content in experimental ulcerative colitis
Авторы
-
Андрей Ю. Ляшев
Курский государственный медицинский университет
https://orcid.org/0000-0001-7170-0416
-
Галина С. Маль
Курский государственный медицинский университет
https://orcid.org/0000-0003-2723-781X
-
Алексей В. Солин
Белгородский государственный национальный исследовательский университет
https://orcid.org/0000-0002-6277-3506
-
Мария А. Баланина
Курский государственный медицинский университет
https://orcid.org/0009-0005-2046-7622
DOI:
https://doi.org/10.18413/rrpharmacology.10.430Аннотация
Introduction: The effectiveness of ulcerative colitis (UC) treatment is fairy moderate and it gives a rise to search for new ways of treating it. Considering the combination of dalargineffects, studying the dalargin influence on the UC development is of undoubted interest. The aim of the study was to evaluate the dalargin effect on the content of transforming growth factor-β (TGF-β) and epidermal growth factor (EGF) in the colonic wall in mice with experimental ulcerative colitis.
Materials and methods: UC was simulated by replacing water with a 5% solution of dextran sodium sulfate in boiled water for 5 days. The mice were killed on the 5th, 7th and 28th days. The concentrations of TGF-β and EGF in the homogenate of the medial colon were determined by enzyme-linked immunosorbent assay using standard kits.
Results and discussion: The dalargin daily subcutaneous administration (dose of 100 μg/kg) for 7 days led to a decrease in TGF-β levels on the 5th and 7th days compared to the control group. In chronic UC, the concentration of TGF-β was higher than in the control group. The EGF concentration was increased in mice with UC treated with dalargin throughout the experiment. There were no differences in dalargin and sulfasalazine effects on the content of TGF-β, and the concentration of EGF throughout the experiment was significantly higher in the animals treated with dalargin.
Conclusion: Effect of dalargin on the TGF-β and EGF concentrations was explained by its stimulating action to opioid μ-receptors localized on immune cells of the colon.
Графическая аннотация
Ключевые слова:
ulcerative colitis, dalargin, transforming growth factor-β, epidermal growth factorБиблиографические ссылки
Bai B, Li H, Han L, Mei Y, Hu C, Mei Q, Xu J, Liu X (2022) Molecular mechanism of the TGF‑β/Smad7 signaling pathway in ulcerative colitis. Molecular Medicine Reports 25 (4): 116. https://doi.org/10.3892/mmr.2022.12632 [PubMed]
Bulgakov SA (2018) Peptide therapeutics in pancreatology. Russian Journal of Evidence-based Gastroenterology [Dokazatel’naya Gastroenterologiya] 7(4): 30–34. https://doi.org/10.17116/dokgastro2018704130 [in Russian]
Chandiran K, Cauley LS (2023) The diverse effects of transforming growth factor-β and SMAD signaling pathway during the CTL response. Frontiers in Immunology 14: 1199671. https://doi.org/10.3389/fimmu.2023.1199671 [PubMed] [PMC]
Du L, Ha C (2020) Epidemiology and pathogenesis of ulcerative colitis. Gastroenterology Clinics of North America 49(4): 643–654.https://doi.org/10.1016/j.gtc.2020.07.005[PubMed]
El Mahdy RN, Nader MA, Helal MG, Abu-Risha SE, Abdelmageed ME (2023) Eicosapentaenoic acid mitigates ulcerative colitis-induced by acetic acid through modulation of NF-κB and TGF-β/EGFR signaling pathways. Life Science 327: 121820 https://doi.org/10.1016/lfs.2023.121820 [PubMed]
Garo LP, Ajay AK, Fujiwara M, Beynon V, Kuhn S, Gabriely G, Sadhukan S, Raheja R, Rubino S, Weiner HL, Murugaiyan G (2019) Smad7 controls immunoregulatory PDL2/1-PD1 signaling in intestinal inflammation and autoimmunity. Cell Reports 28(13): 3353–3366. https://doi.org/1016/j.celrep.2019.07.065 [PubMed] [PMC]
Khomyakova TI, Zolotova NA, Khochanskiy DN, Khomyakov YuN (2013) The modelling of acute and chronic colitis in mice. Treatment and prophylaxis [Lecheniye i Profilaktika] 7(3): 148–159. [in Russian]
Lashgari N-A, Roudsari NM, Zandi N, Pazoki B, Rezaei A, Hashemi M, Momtaz M, Rahimi R, Shayan M, Dehpour AR, Abdolghaffari AH (2021) Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations. Molecular Biology Reports 48(1): 855–874. https://doi.org/10.1007/s11033-020-06095-x [PubMed]
Le Berre C, Honap S, Peyrin-Biroulet L (2023) Ulcerative colitis. Lancet 402(10401): 571–584. https://doi.org/10.1016/S0140-6736(23)00966-2 [PubMed]
Liashev AYu, Mal GS, Solin AV (2023) Investigation of dalargin effectiveness in experimental ulcerative colitis. Experimental and Clinical Pharmacology [Eksperimental’naya i Klinicheskaya Farmacologiya 86(9): 7–11. http://doi.org/10.30906/0869-2092-2023-86-9-7-11 [in Russian]
Liu X, Sun Z, Wang H (2021) Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling. Biotechnic and Histochemistry 96(2): 146–152. https://doi.org/10.1080/10520295.2020.1776896 [PubMed]
Lipatov VA, Severinov DA, Kryukov AA, Saakyan AR (2019a) Ethical and legal aspects of in vivo experimental biomedical research. Part I. I.P. Pavlov Russian Medical Biological Herald [Rossiiskii Medico-Biologicheskii Vestnik Imeni Akademika I.P. Pavlova] 27 (1): 80-92. https://doi.org/23888/PAVLOVJ201927180-92 [in Russian]
Lipatov VA, Severinov DA, Kryukov AA, Saakyan AR (2019b) Ethical and legal aspects of in vivo experimental biomedical research. Part II. I.P. Pavlov Russian Medical Biological Herald [Rossiiskii Medico-Biologicheskii Vestnik Imeni Akademika I.P. Pavlova] 27(2): 245–257. https://doi.org/23888/PAVLOVJ2019272245-257 [in Russian]
Lishmanov YuB, Maslov LN, Naryzhnaya NV, Pei J-M, Kolar F, Zhang Y, Portnichenko AG, Wang H (2012) Endogenous opioid system as a mediator of acute and long-term adaptation to stress. Prospects for clinical use of opioid peptides. Annals of the Russian Academy of Medical Scicences [Vestnic Rossiiskoi Akademii Meditsinskikh Nauk] 6: 73–82. [in Russian]
Lu N, Wang L, Cao H, Liu L, Kaer LV, Washington MK, Rosen MJ, Dube PE, Wilson KT, Ren X, Hao X, Polk DB, Yan F (2014) Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitis. Journal of Immunology 192 (3): 1013-1023. https://doi.org/10.4049/jimmunol.1300133 [PubMed] [PMC]
Luo P, Li X, Gao Y, Zhang Q, Wang Z, Tian X (2022) Central administration of human opiorphin alleviates dextran sodium sulfate-induced colitis in mice through activation of the endogenous opioid system. Frontiers of Pharmacology 13: 904926. https://doi.org/10.3389/fphar.2022.904926 [PubMed] [PMC]
Luo S, Wen R, Wang Q, Zhao Z, Nong F, Fu Y, Huang S, Chen J, Zhou L, Luo X (2019) Rhubarb peony decoction ameliorates ulcerative colitis in mice by regulating gut microbiota to restoring Th17/Treg balance. Journal of Ethnopharmacology 231: 39–49.https://doi.org/10.1016/j.jep.2018.08.033 [PubMed]
Motov VS, Bykova AV, Bykov VV, Khazanov VA, Vengerovskii AI (2021) Protective activity of aminoguanidine derivate on the model of ulcerative colitis in rats. Experimental and Clinical Pharmacology [Eksperimental’naya i Klinicheskaya Farmakologiya] 84(5): 6–10. http://doi.org/10.30906/0869-2092-2021-84-5-6-10 [in Russian]
Naghdalipour M, Moradi N, Fadaei R, Barez SR, Sayyahfar S, Mokhtare M, Fallah S, Esteghamati A (2022) Alteration of miR-21, miR-433 and miR-590 tissue expression related to the TGF-β signaling pathway in ulcerative colitis patients. Archives of Physiology and Biochemistry 128(5): 1170–1174. https://doi.org/10.1080/13813455.2020.1762656[PubMed]
Platonova VV, Sevbitov AV, Shakaryants AA, Dorofeev AE (2018) The experimental clinical substantiation of treatment of patients with odontogenic phlegmon of maxillofacial area using Dаlargin in complex therapy. Clinical and Laboratory Diagnics [Klinicheskaya i Laboratornaya Diagnostika] 63 (5): 293–296. https://doi.org/10.18821/0869-2084-2018-63-5-293-296 [PubMed] [in Russian]
Polikarpova AV, Egorova TV, Bardina MV (2022) Genetically modified animal models of hereditary diseases for testing of gene-directed therapy. Research Results in Pharmacology 8(2): 11–26. https://doi.org/10.3897/rrpharmacology.8.82618
Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG (2020) Metalloproteinases and their inhibitors: potential for the development of new therapeutics. Cell 9(5): 1313. https://doi.org/10.3390/cell9051313 [PubMed] [PMC]
Tatiya-Aphiradee N, Chatuphonprasert W, Jarukamjorn K (2018) Immune response and inflammatory pathway of ulcerative colitis. Journal of Basic and Clinical Physiology and Pharmacology 30(1): 1–10. https://doi.org/10.1515/jbcpp-2018-0036 [PubMed]
Triantafillidis JK, Tzouvala M, Triantafyllidi E (2020) Enteral nutrition supplemented with transforming growth factor-β, colostrum, probiotics, and other nutritional compounds in the treatment of patients with inflammatory bowel disease. Nutrients 12(4): 1048. https://doi.org/10.3390/nu12041048 [PubMed] [PMC]
Yun S-M, Kim S-H, Kim E-H (2019) The molecular mechanism of transforming growth factor-β signaling for intestinal fibrosis: A mini-review. Frontiers in Pharmacology 10: 162. https://doi.org/10.3389/fphar.2019.00162 [PubMed] [PMC]
Zhao D, Cai C, Chen Q, Jin S, Yang B, Li N (2020) High-fat diet promotes DSS-Induced ulcerative colitis by downregulated FXR expression through the TGFB pathway. BioMed Research International 2020: 3516128. https://doi.org/10.1155/2020/3516128 [PubMed] [PMC]
Zhou L, Zhou W, Joseph AM, Chu C, Putzel GG, Fang B, Teng F, Lyu M, Yano H, Andreasson KI, Mekada E, Eberl G, Sonnenberg GF (2022) Group 3 innate lymphoid cells produce the growth factor HB-EGF to protect the intestine from TNF-mediated inflammation. National Immunology 23(2): 251–261. https://doi.org/10.1038/s41590-021-01110-0 [PubMed] [PMC]
Zhu L, Gu P-Q, Shen H (2019) Protective effects of berberine hydrochloride on DSS- induced ulcerative colitis in rats. International Immunopharmacology 68: 242–251. http://doi.org/10.1016/j.intinp.2018.12.036 [PubMed]
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2024 Alexey Solin, Andrei Liashev, Galina Mal
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Русский
English
